Tech Company Financing Transactions
Akarna Therapeutics Funding Round
On 2/17/2016, Akarna Therapeutics announced $15 million in Series B funding from Forbion Capital Partners, New Science Ventures and Third Point.
Transaction Overview
Company Name
Announced On
2/17/2016
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1012 Second St. 210
Encinitas, CA 92007
USA
Encinitas, CA 92007
USA
Phone
Undisclosed
Website
Email Address
Overview
Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases for which there is no approved treatment.
Management Team
Browse more venture capital transactions:
Prev: 2/17/2016: Seven Bridges venture capital transaction
Next: 2/17/2016: Thermedical venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs